Avantor (NYSE:AVTR) PT Raised to $27.00

Avantor (NYSE:AVTR) had its target price raised by Robert W. Baird from $26.00 to $27.00 in a report issued on Monday, Benzinga reports. The brokerage currently has an outperform rating on the stock.

A number of other research firms also recently commented on AVTR. Deutsche Bank Aktiengesellschaft increased their target price on Avantor from $23.00 to $25.00 and gave the stock a hold rating in a report on Thursday, April 18th. Evercore ISI reduced their target price on Avantor from $28.00 to $27.00 and set an outperform rating on the stock in a report on Tuesday, July 2nd. Citigroup downgraded Avantor from a buy rating to a neutral rating and reduced their target price for the stock from $30.00 to $23.00 in a report on Wednesday, July 10th. Royal Bank of Canada increased their target price on Avantor from $30.00 to $31.00 and gave the stock an outperform rating in a report on Monday, July 15th. Finally, Barclays cut their price target on Avantor from $28.00 to $25.00 and set an overweight rating on the stock in a report on Friday, June 28th. Four investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, Avantor presently has a consensus rating of Moderate Buy and an average price target of $27.21.

Avantor Trading Down 1.0 %

Shares of AVTR opened at $26.49 on Monday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.05 and a current ratio of 1.59. The stock has a 50-day moving average price of $22.56 and a 200 day moving average price of $23.76. Avantor has a one year low of $16.63 and a one year high of $28.00. The company has a market capitalization of $18.01 billion, a P/E ratio of 67.92, a P/E/G ratio of 2.82 and a beta of 1.32.

Insider Activity at Avantor

In related news, insider Christophe Couturier 10,000 shares of Avantor stock in a transaction dated Tuesday, July 30th. The was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 1.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Avantor

Several hedge funds have recently modified their holdings of the company. Graypoint LLC increased its position in shares of Avantor by 3.8% during the 1st quarter. Graypoint LLC now owns 11,414 shares of the company’s stock valued at $292,000 after purchasing an additional 423 shares during the period. Vontobel Holding Ltd. increased its position in shares of Avantor by 2.0% during the 4th quarter. Vontobel Holding Ltd. now owns 30,215 shares of the company’s stock valued at $690,000 after purchasing an additional 591 shares during the period. Tokio Marine Asset Management Co. Ltd. increased its position in shares of Avantor by 3.8% during the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 18,725 shares of the company’s stock valued at $427,000 after purchasing an additional 685 shares during the period. Fifth Third Bancorp increased its position in shares of Avantor by 125.3% during the 4th quarter. Fifth Third Bancorp now owns 1,248 shares of the company’s stock valued at $28,000 after purchasing an additional 694 shares during the period. Finally, Wealth Enhancement Advisory Services LLC increased its position in shares of Avantor by 2.8% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 26,921 shares of the company’s stock valued at $571,000 after purchasing an additional 733 shares during the period. 95.08% of the stock is currently owned by institutional investors and hedge funds.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.